Trials / Not Yet Recruiting
Not Yet RecruitingNCT04748939
Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT
Safety and Immunogenicity of a Recombinant Subunit Herpes Zoster Vaccine in Patients With Rheumatic Diseases Undergoing Immunosuppressive or Biologic/Targeted DMARD Therapies: a Double-blind Randomized Placebo-controlled Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Tuen Mun Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies
Detailed description
A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD therapies. Duration of study: 60 weeks
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | recombinant subunit herpes zoster vaccine | vaccine administration |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2025-12-01
- Completion
- 2026-07-01
- First posted
- 2021-02-10
- Last updated
- 2024-08-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04748939. Inclusion in this directory is not an endorsement.